HeyJaredYoko Bian
- Indexed articles, last 90 days
- 2
- Latest publication
- Sep 1, 2026
- Outlet visibility, for Mondaq
- Top 500K sites
- Earliest in this view
- Aug 31, 2026
Latest articles
FDA Approves Ultragenyx’s GENGLYCOS™ Gene Therapy For GSDIa (opens the original)
Read excerpt
On August 19, 2026, Ultragenyx Pharmaceutical announced that the FDA granted accelerated approval to its GENGLYCOS™ (pariglasgene brecaparvovec-opnr) for patients eight years and older with glycogen storage disease type Ia (GSDIa). The therapy is approved to reduce daily cornstarch intake as an adjunct to nutritional management. It is the first FDA-approved treatment for GSDIa and Ultragenyx’s first approved gene therapy. GSDIa is a rare genetic disorder that prevents the liver from properly rel
Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars (opens the original)
Read excerpt
On August 21, 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical (“Lotus”) for AVT34, a proposed biosimilar to IMFINZI® (durvalumab), and AVT87, a proposed biosimilar to HEMLIBRA® (emicizumab). In the United States, Alvotech and Lotus will have semi-exclusive commercialization rights, with Lotus commercializing through its subsidiary Alvogen. Alvotech will remain responsible for development, U.S. marketing authorizations, and product supply. Lotus will
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Mondaq, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.